{"disease":{"id":"newly-diagnosed","name":"newly diagnosed"},"drugs":{"marketed":[{"drug_id":"asciminib","indication_name":"Newly diagnosed Ph+ CML in CP","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Scemblix","generic_name":"ASCIMINIB","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase ABL1","drug_class":"","quality_score":69,"revenue":"894","mechanism":"Scemblix works by blocking the ABL1 enzyme, which is involved in the growth and survival of cancer cells."},{"drug_id":"gemtuzumab","indication_name":"newly-diagnosed CD33-positive acute myeloid leukemia (AML)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mylotarg","generic_name":"GEMTUZUMAB","company_name":"Wyeth Pharms Inc","drug_phase":"marketed","molecular_target":"Myeloid cell surface antigen CD33","drug_class":"CD33-directed Immunoconjugate [EPC]","quality_score":10,"revenue":"100","mechanism":"Mylotarg targets and binds to CD33-positive cancer cells, delivering a cytotoxic agent to destroy them."},{"drug_id":"gemtuzumab-ozogamicin","indication_name":"Newly-diagnosed CD33-positive AML","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mylotarg","generic_name":"gemtuzumab-ozogamicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Myeloid cell surface antigen CD33","drug_class":"CD33-directed Immunoconjugate [EPC]","quality_score":68,"revenue":"100","mechanism":"Mylotarg works by binding to CD33 on cancer cells and releasing a toxic compound that kills the cells."},{"drug_id":"chembl-chembl1201506","indication_name":"Newly-diagnosed CD33-positive AML","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"GEMTUZUMAB OZOGAMICIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CD33-directed Immunoconjugate [EPC]","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl941","indication_name":"Newly Diagnosed Ph+ CML","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IMATINIB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":12,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl941","indication_name":"Newly Diagnosed Ph+ ALL in Pediatrics","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IMATINIB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":12,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl3545131","indication_name":"Newly Diagnosed Multiple Myeloma (Not Eligible for ASCT)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ISATUXIMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Light Chain (AL) Amyloidosis in combination with bortezomib, cyclophosphamide and dexamethasone in newly diagnosed patients","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in newly diagnosed patients who are eligible for autologous stem cell transplant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma in combination with bortezomib, lenalidomide, and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"thalidomide","indication_name":"Newly Diagnosed Multiple Myeloma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Thalomid","generic_name":"THALIDOMIDE","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"thalidomide","quality_score":67,"revenue":null,"mechanism":"Thalomid works by inhibiting the production of tumor necrosis factor, a protein that promotes inflammation and tumor growth."},{"drug_id":"ponatinib-hydrochloride","indication_name":"Newly diagnosed Ph+ ALL","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PONATINIB HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"ABL, T315I mutant ABL, VEGFR, PDGFR, FGFR, EPH receptors, SRC family, KIT, RET, TIE2, FLT3","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Ponatinib inhibits multiple kinases, including ABL and its T315I mutant, reducing tumor size in mice."}],"pipeline":[],"offLabel":[],"totalMarketed":15,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06857071","title":"Expanded Social Network Recruitment to HIV Testing (E-SNRHT) Intervention to Locate Undiagnosed Cases and Reduce HIV-related Stigma","phase":"NA","overall_status":"RECRUITING","enrollment_count":2480,"lead_sponsor_name":"University of Illinois at Chicago","has_results":false},{"nct_id":"NCT00919750","title":"Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors","phase":"","overall_status":"COMPLETED","enrollment_count":1258,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT03522246","title":"A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1097,"lead_sponsor_name":"pharmaand GmbH","has_results":true},{"nct_id":"NCT07474142","title":"A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve Prostate Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Xijing Hospital","has_results":false},{"nct_id":"NCT06810791","title":"HVA vs IA/DA or VA in the Treatment of ND HR-AML","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":876,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT05516927","title":"The Sanderson Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening","phase":"","overall_status":"COMPLETED","enrollment_count":788,"lead_sponsor_name":"Freenome Holdings Inc.","has_results":false},{"nct_id":"NCT03345095","title":"A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":749,"lead_sponsor_name":"European Organisation for Research and Treatment of Cancer - EORTC","has_results":true},{"nct_id":"NCT05520892","title":"Two Regimens of IVIG in the Treatment of Newly Diagnosed ITP in Children","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":580,"lead_sponsor_name":"Fujian Medical University Union Hospital","has_results":false},{"nct_id":"NCT06679101","title":"A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":520,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT07296627","title":"Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT06457035","title":"Development and Validation of a Nomogram for Predicting Surgery in Newly-diagnosed Crohn's Disease: a Retrospective Cohort Study","phase":"","overall_status":"COMPLETED","enrollment_count":490,"lead_sponsor_name":"First Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT01844986","title":"Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":450,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT03642041","title":"Study of Smoking Trajectory in Newly Diagnosis Lung Cancer Patients","phase":"","overall_status":"COMPLETED","enrollment_count":406,"lead_sponsor_name":"National Defense Medical Center, Taiwan","has_results":false},{"nct_id":"NCT06495814","title":"Characterization and Mechanism Research of the Pre-disease State of Obese Type 2 Diabetes Mellitus","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":380,"lead_sponsor_name":"Fengmei Lian","has_results":false},{"nct_id":"NCT03972982","title":"Effects of Structured Simplified Short-term Intensive Insulin Therapy on Long-term Glycemic Remission","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":330,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04994717","title":"Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":304,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT07053436","title":"Horizon Two Adaptive Platform Study in High Risk Newly Diagnosed Multiple Myeloma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Multiple Myeloma Research Consortium","has_results":false},{"nct_id":"NCT05853887","title":"Liquid Biopsy Based NGS in Newly Diagnosed NSCLC","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":260,"lead_sponsor_name":"Charu Aggarwal","has_results":false},{"nct_id":"NCT05163080","title":"SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":247,"lead_sponsor_name":"MimiVax, LLC","has_results":false},{"nct_id":"NCT03258931","title":"Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":214,"lead_sponsor_name":"Arog Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT00575718","title":"Smoking Cessation Intervention for Cancer Patients","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":204,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT07021339","title":"Anterior Temporal Lobectomy in Temporal Glioblastoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":178,"lead_sponsor_name":"University Hospital, Bonn","has_results":false},{"nct_id":"NCT06532552","title":"Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":172,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT07247097","title":"ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":160,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT04600817","title":"A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":160,"lead_sponsor_name":"TJ Biopharma Co., Ltd.","has_results":false},{"nct_id":"NCT02632708","title":"Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":153,"lead_sponsor_name":"Institut de Recherches Internationales Servier","has_results":false},{"nct_id":"NCT03173248","title":"Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":146,"lead_sponsor_name":"Institut de Recherches Internationales Servier","has_results":true},{"nct_id":"NCT05561049","title":"Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma","phase":"","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT07514936","title":"Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT07087964","title":"Positron Emission Tomography With Innovative Laboratory Techniques for Improved Risk and Disease Assessment in Newly Diagnosed Multiple Myeloma Patients","phase":"","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Universiteit Antwerpen","has_results":false},{"nct_id":"NCT05447195","title":"Phase 2 Study of CAN008 in Subjects With GBM","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":117,"lead_sponsor_name":"CANbridge Life Sciences Ltd.","has_results":false},{"nct_id":"NCT04271189","title":"Managing DIabetes Remission After Combined Therapy in EarLy Stage of DiabetEs","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":108,"lead_sponsor_name":"Azienda Ospedaliero-Universitaria di Parma","has_results":false},{"nct_id":"NCT05506410","title":"A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Zhengzhou University","has_results":false},{"nct_id":"NCT04840069","title":"Radiotherapy Planning Using Fluciclovine PET in Patients With Newly Diagnosed Glioblastoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"St. Joseph's Hospital and Medical Center, Phoenix","has_results":false},{"nct_id":"NCT03631862","title":"Treatment of Newly Diagnosed Peripheral T-cell Lymphoma","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Zhengzhou University","has_results":false},{"nct_id":"NCT03832725","title":"Pathobiology of Remission of Type 2 Diabetes","phase":"NA","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"University of Tennessee","has_results":false},{"nct_id":"NCT07343609","title":"Predictive Value of Seizure Frequency at Onset for Long-Term Seizure Control","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT05284591","title":"Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of First-line Daratumumab, Lenalidomide, Dexamethasone (DRd) Multiple Myeloma Patients in Germany Depending on Application Route (sc or iv)","phase":"","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"iOMEDICO AG","has_results":false},{"nct_id":"NCT07308301","title":"Examination of the Relationship Between Quality of Life and Caregiving Burden Among Caregivers of Pediatric Oncology Patients","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":95,"lead_sponsor_name":"Fatma Beyza Akdeniz","has_results":false},{"nct_id":"NCT02315326","title":"Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":93,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT05566054","title":"Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":92,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT06816927","title":"Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":92,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT06324266","title":"Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for Transplantation","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Jinling Hospital, China","has_results":false},{"nct_id":"NCT06683885","title":"A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Mingzhi Zhang","has_results":false},{"nct_id":"NCT01805453","title":"Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT04667988","title":"JAK2 Mutation May Predict Response and Guide First Line Treatment in Rheumatoid Arthritis","phase":"NA","overall_status":"COMPLETED","enrollment_count":76,"lead_sponsor_name":"Mansoura University","has_results":false},{"nct_id":"NCT05088330","title":"A Study to Access of Daratumumab Combined With VRD in the Treatment of Patients With Standard-risk Newly Diagnosed MM","phase":"NA","overall_status":"UNKNOWN","enrollment_count":76,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT05259553","title":"Biomarkers in Multiple Myeloma","phase":"NA","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Centre Hospitalier Universitaire de Saint Etienne","has_results":false},{"nct_id":"NCT04477200","title":"Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":68,"lead_sponsor_name":"University of Michigan Rogel Cancer Center","has_results":false},{"nct_id":"NCT01790503","title":"A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"Daiichi Sankyo","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}